Physician profile
Macy Vanarnam
NPI 1669908794
$389.49
in general payments reported to CMS, 2019-2025
14 companies · $49.65 in 2025
The $49.65 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.70 · 2020: $31.59 · 2021: $13.51 · 2022: $86.40 · 2023: $116 · 2024: $59.27 · 2025: $49.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $225.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $112.77 | 2020-2025 | Orilissa |
| Pacira Pharmaceuticals Incorporated | $38.16 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.41 | 2022 | |
| Astellas Pharma US INC | $25.67 | 2024 | Veozah |
| Smith+Nephew, INC. | $24.40 | 2023 | Pico 7 |
| Myriad Genetic Laboratories, INC. | $22.80 | 2025 | Myrisk |
| Daiichi Sankyo INC. | $21.81 | 2023 | Injectafer |
| Solventum Corporation | $20.18 | 2024 | Activ.A.C. |
| Lupin INC. | $16.80 | 2019 | |
| Sumitomo Pharma America, INC. | $16.61 | 2023 | Myfembree |
| Foundation Medicine, INC. | $15.90 | 2019 | |
| Novo Nordisk INC | $15.88 | 2023 | Wegovy |
| Pfizer INC. | $15.68 | 2023 | |
| Merck Sharp & Dohme LLC | $13.42 | 2024 | Gardasil, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Macy Vanarnam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.